New York Rep. Chris Collins, who faces insider trading charges stemming from his investment in an Australian biotech company, will get his day in court on Feb. 3, 2020.

Assistant U.S. Attorney Scott Hartman repeatedly asked to move up the trial date, stating there is a “strong public interest in seeing this case resolved in 2019,” CNN reported.

Federal prosecutors say the congressman received insider information that Innate Immunotherapeutics’ only drug failed a crucial clinical trial while he was attending the White House Congressional picnic in June 2017.

“Wow. Makes no sense. How are these results even possible???” Collins replied in an email to the company’s chief executive, according to the indictment.

Federal prosecutors say Collins then tipped his son, Cameron Collins, who unloaded enough shares in the next two days to skate $570,900 in losses. Cameron Collins then told four people, including his girlfriend and his girlfriend’s father, who told two others.